Groupe d'Etude en Oncologie du Quebec

Title	A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Protocole ID	QUINTESSENTIAL
ClinicalTrials.gov ID	NCT06297226
Cancer Type(s)	Myeloma
Phase	Phase II
Stage	Relapse/refractory (2nd line and more)
Study Type	Clinical
Drug	BMS-986393
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1
City
Principal Investigator	Dr. Chaim Shustik Dr. Michael Sebag
Coordinator	Nancy Renouf 514-934-1934 poste 35718
Status	Recruiting
Activation Date
Eligibility Criteria	Documented diagnosis of multiple Mmyeloma (MM) as per International Myeloma Working Group (IMWG) criteria. Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and anti-B cell maturation antigen (BCMA) therapy], and at least 3 prior lines of therapy (LOT). Documented disease progression during or after their last anti-myeloma regimen as per IMWG. Participants must have measurable disease during screening. Have measurable disease during screening. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria	Active or history of central nervous system involvement with MM. Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis. Other protocol-defined Inclusion/Exclusion criteria apply.

Groupe d'étude en oncologie du Québec